No prescriptions of any NSAID within one year before enrollment.
Treatment groups and follow-up
Each eligible participant is randomly assigned to either the treatment or the control group. Those in the treatment group receive a predefined daily dose of diclofenac for the duration of the trial. Those in the placebo group receive matching placebo pills if the trial has a blind design, no pills (i.e., usual care with, e.g., training, physiotherapy, and paracetamol) if the trial has an open-label design, or alternative low-risk treatment (e.g., low-dose ibuprofen or naproxen) if the trial has an active-control design. Cardiovascular diagnoses are confirmed by a physician who is also unaware of the treatment assignment if the trial is double-blind. Each participant is followed until first occurrence of an outcome, death, loss to followup, or administrative end of the study after 30 days, whichever occurred first.
Eligible individuals were classified into four overall groups: diclofenac initiators, active NSAID comparators (ibuprofen or naproxen), active non-NSAID comparator (paracetamol), and non-user comparator. Initiation was defined as filling a prescription during the month of January 1996 (in the active treatment groups) and the subsequent 251 months. Each individual was followed until first occurrence of an outcome, death, loss to follow-up, or administrative end of the study 30 days, whichever occurred first. 
Women
Atrial fibrillation/flutter 1.2 (1.0 to 1.4) 1.1 (0.9 to 1.3) 1.7 (1.2 to 2.6) 1.4 (0.9 to 2.0) 1.4 (1.2 to 1.8) 1.5 (1.2 to 1.9) Ischemic stroke 1.5 (1.2 to 1.9) 1.4 (1.1 to 1.7) 3.1 (1.5 to 6.3) 2.4 (1.2 to 5.1) 1.2 (0.9 to 1.5) 2.1 (1.5 to 3.0) Heart failure 1.2 (1.0 to 1.5) 1.1 (0.9 to 1.3) 1.8 (1.1 to 2.9) 1.3 (0.8 to 2.2) 1.1 (0.9 to 1.5) 1.9 (1.5 to 2.5) Myocardial infarction 1.2 (0.9 to 1.4) 1.1 (0.9 to 1.3) 1.9 (1.1 to 3.2) 1.5 (0.9 to 2.6) 1.2 (0.9 to 1.6) 2.0 (1.5 to 2.7) Cardiac death 2.0 (1.6 to 2.5) 1.8 (1.4 to 2.3) 2.4 (1.3 to 4.2) 1.7 (1.0 to 3.1) 1.2 (0.9 to 1.6) 2.2 (1.6 to 3.0) MACE 1.3 (1.2 to 1.5) 1.2 (1.1 to 1.3) 2.0 (1.6 to 2.6) 1.6 (1.2 to 2.0) 1.2 (1.1 to 1.4) 1.9 (1.6 to 2.1) Men Atrial fibrillation/flutter 1.4 (1.2 to 1.6) 1.2 (1.0 to 1.4) 1.2 (0.9 to 1.7) 1.3 (0.9 to 1.8) 1.3 (1.0 to 1.6) 1.1 (0.9 to 1.3) Ischemic stroke 1.3 (1.1 to 1.7) 1.2 (0.9 to 1.5) 0.8 (0.5 to 1.3) 0.8 (0.5 to 1.3) 1.4 (1.0 to 1.9) 1.3 (0.9 to 1.7) Heart failure 1.4 (1.1 to 1.7) 1.2 (1.0 to 1.5) 1.5 (1.0 to 2.4) 1.6 (1.0 to 2.6) 1.2 (1.0 to 1.6) 1.5 (1.2 to 2.0) Myocardial infarction 1.5 (1.3 to 1.8) 1.3 (1.2 to 1.6) 1.2 (0.9 to 1.8) 1.3 (0.9 to 1.8) 1.5 (1.2 to 1.9) 1.8 (1.4 to 2.2) Cardiac death 1.4 (1.1 to 1.8) 1.2 (0.9 to 1.5) 1.0 (0.6 to 1.7) 1.0 (0.6 to 1.7) 0.8 (0.6 to 1.1) 1.3 (0.9 to 1.7) MACE 1.4 (1.3 to 1.6) 1.3 (1.1 to 1.4) 1.1 (0.9 to 1.4) 1.2 (1.0 to 1.4) 1.2 (1.1 to 1.4) 1.3 (1.2 to 1.5) 18-49 years Atrial fibrillation/flutter 1.6 (1.1 to 2.3) 1.5 (1.0 to 2.2) 1.7 (0.7 to 4.0) 1.4 (0.6 to 3.3) 1.2 (0.6 to 2.5) 0.9 (0.6 to 1.4) Ischemic stroke 1.6 (1.0 to 2.4) 1.6 (1.0 to 2.4) 1.8 (0.6 to 5.2) 1.5 (0.5 to 4.4) 1.7 (0.8 to 3.6) 2.5 (1.3 to 4.9) Heart failure 1.8 (1.1 to 3.2) 1.8 (1.0 to 3.2) --0.6 (0.2 to 1.4) 2.2 (1.0 to 4.9) Myocardial infarction 2.1 (1.5 to 2.9) 2.0 (1.5 to 2.8) 2.8 (1.2 to 6.6) 2.4 (1.0 to 5.5) 1.3 (0.7 to 2.2) 2.4 (1.6 to 3.7) Cardiac death 2.0 (1.0 to 4.2) 2.0 (0.9 to 4.1) 1.4 (0.3 to 6.6) 1.3 (0.3 to 5.9) 1.4 (0.5 to 4.0) 1.0 (0.4 to 2.2) MACE 1.7 (1.4 to 2.1) 1.7 (1.4 to 2.0) 2.2 (1.4 to 3.6) 1.9 (1.1 to 3.1) 1.2 (0.9 to 1.7) 1.6 (1.2 to 2.0) 50-69 years Atrial fibrillation/flutter 1.3 (1.1 to 1.6) 1.3 (1.1 to 1.5) 1.5 (0.9 to 2.3) 1.5 (1.0 to 2.3) 1.4 (1.1 to 1.8) 1.1 (0.9 to 1.4) Ischemic stroke 1.1 (0.9 to 1.5) 1.1 (0.8 to 1.5) 0.9 (0.5 to 1.6) 0.9 (0.5 to 1.6) 0.9 (0.6 to 1.2) 1.5 (1.1 to 2.2) Heart failure 1.2 (0.9 to 1.6) 1.2 (0.9 to 1.5) 1.7 (0.9 to 3.2) 1.8 (0.9 to 3.3) 1.1 (0.8 to 1.5) 2.2 (1.5 to 3.2) Myocardial infarction 1.2 (1.0 to 1.4) 1.2 (1.0 to 1.4) 1.6 (1.0 to 2.5) 1.7 (1.0 to 2.6) 1.3 (1.0 to 1.7) 1.9 (1.5 to 2.4) Cardiac death 1.4 (1.0 to 2.0) 1.4 (1.0 to 1.9) 1.2 (0.6 to 2.4) 1.2 (0.6 to 2.4) 0.9 (0.6 to 1.4) 1.5 (1.0 to 2.4) MACE 1.3 (1.1 to 1.4) 1.2 (1.1 to 1.4) 1.3 (1.0 to 1.7) 1.3 (1.0 to 1.7) 1.1 (1.0 to 1.3) 1.5 (1.3 to 1.7) 70 years or more Atrial fibrillation/flutter 1.0 (0.9 to 1.2) 1.0 (0.9 to 1.2) 1.2 (0.8 to 1.6) 1.2 (0.9 to 1.7) 1.4 (1.1 to 1.7) 1.5 (1.3 to 1.9) Ischemic stroke 1.3 (1.0 to 1.6) 1.3 (1.0 to 1.6) 1.5 (0.8 to 2.7) 1.5 (0.8 to 2.7) 1.6 (1.2 to 2.2) 1.6 (1.2 to 2.2) Heart failure 1.1 (0.9 to 1.3) 1.1 (0.9 to 1.3) 1.2 (0.8 to 1.8) 1.2 (0.8 to 1.8) 1.3 (1.1 to 1.7) 1.6 (1.3 to 2.1) Myocardial infarction 1.1 (0.9 to 1.3) 1.1 (0.9 to 1.3) 0.8 (0.6 to 1.3) 0.9 (0.6 to 1.3) 1.5 (1.1 to 1.9) 1.7 (1.3 to 2.3) Cardiac death 1.5 (1.2 to 1.8) 1.5 (1.2 to 1.8) 1.4 (0.9 to 2.3) 1.4 (0.9 to 2.3) 1.1 (0.8 to 1.3) 2.0 (1.6 to 2.6) MACE 1.1 (1.0 to 1.3) 1.1 (1.0 to 1.3) 1.2 (1.0 to 1.5) 1.2 (1.0 to 1.5) 1.3 (1.2 to 1.5) 1.7 (1.5 to 1.9)
Abbreviations: MACE, major adverse cardiovascular events; PS, propensity score * Estimated by the hazard ratio. † Propensity score-matched paracetamol initiators. ‡ Propensity score-matched health care seekers from the general population with no NSAID use. 
